AKT1 and breast carcinoma: The first pan-AKT inhibitor of hormone receptor positive/HER2+ negative advanced or metastatic breast cancers, Capivasertib, was approved only recently in 2023 by FDA, increasing therefore the interest toward AKT/PI3K targeted therapies.